Q4 Earnings Estimate for OPKO Health Issued By HC Wainwright

OPKO Health, Inc. (NASDAQ:OPK) – Equities research analysts at HC Wainwright cut their Q4 2026 earnings per share estimates for shares of OPKO Health in a report released on Monday, March 2nd. HC Wainwright analyst Y. Chen now anticipates that the biotechnology company will earn ($0.08) per share for the quarter, down from their prior estimate of ($0.07). The consensus estimate for OPKO Health’s current full-year earnings is ($0.25) per share.

OPKO Health (NASDAQ:OPK) last issued its earnings results on Thursday, February 26th. The biotechnology company reported ($0.04) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.07) by $0.03. OPKO Health had a negative return on equity of 17.42% and a negative net margin of 37.19%.The company had revenue of $148.50 million for the quarter, compared to analyst estimates of $139.76 million. During the same period in the prior year, the firm earned $0.01 earnings per share. OPKO Health’s revenue for the quarter was down 19.1% on a year-over-year basis.

A number of other research analysts have also recently issued reports on OPK. Weiss Ratings reiterated a “sell (d-)” rating on shares of OPKO Health in a report on Thursday, January 22nd. JPMorgan Chase & Co. initiated coverage on OPKO Health in a research note on Thursday, November 20th. They set a “neutral” rating for the company. Barrington Research decreased their price objective on OPKO Health from $2.25 to $1.50 and set an “outperform” rating for the company in a report on Monday. Finally, Wall Street Zen upgraded OPKO Health from a “sell” rating to a “hold” rating in a report on Sunday, December 21st. One research analyst has rated the stock with a Strong Buy rating, two have assigned a Buy rating, three have assigned a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the company presently has an average rating of “Hold” and a consensus price target of $2.03.

OPKO Health Stock Performance

Shares of OPK stock opened at $1.20 on Thursday. The company has a current ratio of 3.97, a quick ratio of 3.32 and a debt-to-equity ratio of 0.26. The firm has a fifty day simple moving average of $1.26 and a two-hundred day simple moving average of $1.35. OPKO Health has a 12 month low of $1.11 and a 12 month high of $2.04. The firm has a market capitalization of $910.88 million, a PE ratio of -4.00 and a beta of 1.50.

Institutional Inflows and Outflows

A number of institutional investors have recently bought and sold shares of the business. Caitong International Asset Management Co. Ltd increased its position in shares of OPKO Health by 1,056.9% during the 4th quarter. Caitong International Asset Management Co. Ltd now owns 39,232 shares of the biotechnology company’s stock valued at $49,000 after purchasing an additional 35,841 shares during the last quarter. Virtu Financial LLC bought a new position in OPKO Health during the fourth quarter valued at about $145,000. EP Wealth Advisors LLC purchased a new stake in OPKO Health during the fourth quarter worth about $37,000. XTX Topco Ltd bought a new stake in OPKO Health in the fourth quarter worth about $432,000. Finally, Zacks Investment Management bought a new stake in OPKO Health in the fourth quarter worth about $27,000. Institutional investors own 64.63% of the company’s stock.

About OPKO Health

OPKO Health, Inc (NASDAQ:OPK) is a diversified, global healthcare company headquartered in Miami, Florida, with a focus on diagnostics, pharmaceuticals and biologics development. The company operates two main business segments—Laboratory Services and Pharma Services & Products—driven by its mission to advance patient care through innovation in testing and targeted therapies.

In its Laboratory Services segment, OPKO leverages BioReference Laboratories, one of the largest full-service commercial labs in the United States.